Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1991;117(5):425-30.
doi: 10.1007/BF01612762.

High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells

Affiliations
Comparative Study

High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells

J Koberda et al. J Cancer Res Clin Oncol. 1991.

Abstract

Adherent lymphokine-activated killer cells (A-LAK) are highly potent cytotoxic cells, which are shown to be derived not only from natural killer (NK)/K cells but phenotypically also from T cells. The generation and phenotypical and functional characterisation of these T-cell-derived A-LAK are described. In contrast to non-adherent cells (NA-LAK) and unseparated LAK (UN-LAK), these mostly CD3+ CD56+ CD8+ cells display a high degree of expansion following initial interleukin-2 (rIL-2) activation and further culturing in autologous conditioned medium. A comparison of cytotoxic activities of cultured cells reveals a significantly higher oncolytic ability of A-LAK cells against both K562 and Daudi cells than that of cultured controls of NA-LAK and UN-LAK. In addition, A-LAK are characterised by a marked endogenous cytokine release of interferon gamma, tumour necrosis factor alpha and IL-6 as well as by their shedding of p55 IL-2 receptor after exposure to IL-2. The results demonstrate A-LAK to be the lymphocyte subpopulation with the most cytotoxic activity and endogenous cytokine release after exposure to IL-2. The improvement of techniques for long-term cultures may be of interest for future therapeutic approaches.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bergmann L (1990) The clinical significance of IL-2. Onkologie 13:416–422 - PubMed
    1. Bergmann L, Mitrou PS, Weidmann E, Schmidt-Mathiesen A, Hanke P, Hoelzer D (1989) In vitro and in vivo induction of lymphokine activated killer (LAK) cells in patients with gastric cancer and other solid tumors. In: Koldovsky et al. (eds) Lymphokines in cancer. Springer, Berlin Heidelberg New York, pp 32–43
    1. Bergmann L, Weidmann E, Bungert B, Hechler P, Mitrou PS (1990a) Influence of various cytokines on the induction of lymphocyte activated killer (LAK) cells. Nat Immun Growth Regul 9:256–273 - PubMed
    1. Bergmann L, Keilholz U, Bartsch U, Weidmann E, Runne U, Mitrou PS (1990b) Combination of interleukin-2 and interferon-alpha in the treatment of advanced renal cell carcinoma and malignant melanoma. Study design and preliminary results. Onkologie 11:137–140 - PubMed
    1. Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Gianella G, Montesoro E, Mastroberardino G, Isacchi G, Testa U, Calabresi F, Peschle C (1990) Adoptive immunotherapy of human cancer: the cytokine cascade and monocate activation following high-dose interleukin-2 bolus treatment. Cancer Res 50:5795–5800 - PubMed

Publication types

MeSH terms

LinkOut - more resources